Radiation enhanced therapy for tumors expressing a gene for viral thymidine kinase in the presence of a 5-halogengated pyrimidine
US5985266A · kind A · utility
4Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 1997 |
| Grant date | Nov 16, 1999 |
| Priority date | — |
| Expiry date | Jul 30, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to combination radio therapy of tumors and more specifically to pharmaceutical compositions, and methods of treatment by gene therapy designed to sensitize tumors in animals, notably humans, and render them more susceptible to radiation, thus significantly reducing the amount of radiation required to kill neoplastic cells while at the same time making the radiation far more tissue specific to the tumor site.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.